OUR VISION: is to be the leading specialty CNS company

with therapies in several neurological

conditions with few, if any, treatment options.

OUR CULTURE:We are proud to have the most talented colleagues

working together to develop and market drugs that we hope will make a difference in the lives of millions of

patients. We foster an inclusive environment of diverse, committed and highly accomplished people who respect

each other. Together, we live the Avanir values as we

continue advancing science to serve patients.

PRODUCTS:dextromethorphan HBr

and quinidine sulfate

capsules

AVANIR PHARMACEUTICALSWe are a global biotechnology company focused on improving patients’ lives by acquiring, developing and commercializing novel therapeutic products for the treatment of central nervous system (CNS) disorders.We are relentlessly focused and committed to serving

patients suffering from CNS disorders. We do this by

adhering to the following principles:

• Advancing innovative treatments and cures

• Excelling in scientific development

• Bringing passion to everything we do

QUICK FACTS:President & CEO: Rohan Palekar

Jim Beitel, Vice President, Corporate Development & OperationsGarlan Adams, Vice President & General Counsel

Hisanori Maei, Vice President, Business Planning & Alliance ManagementDan Dalton, SVP, Chief Compliance Officer

Rick Malamut, SVP, R&D & Chief Medical Officer

sumatriptan nasal powder

11 mg per nosepiece

HEADQUARTERS: 30 ENTERPRISE, SUITE 400, ALISO VIEJO, CA 92656WWW.AVANIR.COM | 949-389-6700

Employees: 648+ | Parent Company: Otsuka Pharmaceuticals Co., Ltd.

MID-1990S, COMPANY CHANGES NAME TO AVANIR PHARMACEUTICALS, WITH A FOCUS ON AREAS OF CARDIOVASCULAR, AUTOIMMUNE AND INFECTIOUS DISEASES

PIPELINE:

HISTORY:

1988

2011 20151990S

2010

2013

2012

2016Avanir started out as Lidak Pharmaceuticals, Inc. in 1988, developing research-based treatments to meet patient needs. Our firstpharmaceutical product was Abreva®, an over-the-counter cold sore treatment that was out-licensed to another company.

In 2015, Avanir became a subsidiary of Otsuka America, Inc., a holdingcompany owned by Otsuka Pharmaceutical Co., Ltd. This move providedthe support of a leading global pharmaceutical company while allowingour business to remain nimble and flexible.

Our quest to bring research-based treatments to patients led us to develop treatments for cardiovascular, autoimmune and infectious diseases. We also changed our name to Avanir Pharmaceuticals, Inc.

In October, we received an FDA approval for NUEDEXTA® (dextromethorphan hydrobromide) with a 20 / 10 mg dose strength.

*product is currently not marketed in Europe

In June, the European Commision approved NUEDEXTA®(dextromethorphan hydrobromide and quinidine sulfate) with a 20/10 mg and 30/10 mg dose strength. On July 2, we announced a development andcommercialization agreement with OptiNose™ AS for a new investigational product for the acute treatment of migraine.

We entered into a license agreement with Concert Pharmaceuticals,Inc. to develop and commercialize deuterium-modifieddextromethorphan for disorders of the central nervous system.

NUEDEXTA® is launched in the United States

We received FDA approval of ONZETRA® Xsail® (sumatriptan nasal powder) 11 mg pernosepiece in January and launched it in the United States market in May.

1999During this pivotal year, we began development of products containing dextromethorphan - a key ingredient in our CNS-focused approved product and many drugs under development.

2007Avanir became a publicly traded company, listed on the NASDAQ stock exchange.

30 Enterprise, Suite 400, Aliso Viejo CA 92656 | 949-389-6700 | www.avanir.com

AVP-825Acute Migraine in Pediatrics

AVP-786Agitation in Alzheimer’s Disease

Residual Schizophrenia

Disinhibition in Dementia

Traumatic Brain Injury Behavioral Dysfunction

Milestone

RESEARCH CLINICAL ACTIVITIES

PRE-CLIN PHASE 1 PHASE 2 PHASE 3 APPROVED

AVANIR: Neuroscience PipelineStrong R&D Commitment to Neurologic and Psychiatric Diseases

(PLANNED)

(PLANNED)